The Science

CPEP research found one-third of participants experienced post-psychedelic difficulties lasting over a year.

In 115 real-world patients with treatment-resistant conditions, psilocybin-assisted therapy significantly reduced both depression (p < 0.001, η² = 0.42) and anxiety (p < 0.001) — with zero serious adverse events or dropouts.

A clinical trial found that microdose psilocybin was safe and feasible in palliative care, with 69% of participants reporting meaningful global improvement and 72% showing significant reductions in demoralization — suggesting it may offer a scalable, low-risk option for existential and psychological distress near the end of life.

Trauma and chronic stress alter amygdala and hippocampal function, impairing emotional regulation and threat discrimination.

Psilocybin enhanced the brain’s ability to unlearn fear responses across stress-naive, acutely stressed, and chronically stressed conditions, suggesting it may support fear processing even in individuals with trauma or chronic stress histories.

In 2021, 359 million people worldwide had an anxiety disorder; only 27.6% received treatment.

Psychedelic therapy enhances self-compassion while reducing shame and self-criticism, with the quality of the experience — not just the drug — predicting long-term therapeutic outcomes across diagnostic groups.

• Depression is a common mental disorder.
• Globally, an estimated 5.7% of adults suffer from depression.
• More women are affected by depression than men.
• Depression can lead to suicide.
• There is effective treatment for mild, moderate and severe depression.

Single 25mg dose well tolerated, rapid and durable improvement in PTSD symptoms out to 12 weeks. No serious adverse events.

73 participants, randomized double-blind placebo-controlled. Statistically significant improvements across all primary and secondary endpoints. No serious adverse events.

73 participants, randomized double-blind placebo-controlled. Statistically significant improvements across all primary and secondary endpoints. No serious adverse events.

Study suggests that psilocybin-assisted therapy results in substantial decreases in depressive symptoms across studies to date.

A systematic review of 30 RCTs found that psychotherapeutic interventions for prolonged grief disorder produce meaningful improvements, with experiential approaches combining exposure, EMDR, and mindfulness showing particular promise for trauma-related grief — pointing toward the need for personalized, body-inclusive treatment models

Lifetime psychedelic use was linked to reduced alcohol use (66%), improved eating habits (49%), and decreased aggression (72%)

CBMPs were associated with improvements in PTSD symptoms, anxiety, sleep, and HRQoL at up to 18 months

Acceptance and reappraisal to lower anger.

Lower trait Shame associated with better post-psilocybin psychological outcomes

Psychedelics may temporarily elevate right-hemisphere dominance — mirroring meditation’s effects on empathy, mindfulness, and emotional insight

Meditation and body-based practices associated with neuroplasticity, reduced amygdala reactivity, and improved emotional regulation.

Across 5 RCTs and 472 patients, psilocybin outperformed controls on anxiety in 80% of studies and depression in 60% — with comparable dropout rates and no serious safety concerns.

A Cornell University study found that psilocybin enhanced the brain’s ability to unlearn conditioned fear responses, with the effect dependent on dose, context, and serotonin receptor activation — offering a preclinical basis for psilocybin-assisted PTSD treatment.

World’s largest brain study of childhood trauma; found disruption in neural networks governing emotional processing, self-understanding, and empathy.

Therapeutic psilocybin showed no increased risk of paranoia or thought disorders across 528 patients — with mild side effects resolving within 48 hours

Across 61 RCTs and 5,956 participants, mind-body exercise significantly reduced anxiety (SMD = 0.454, p < 0.001) — with sessions over 60 minutes showing the strongest effects.

Tai Chi was considered an effective approach for improving anxiety and depression.

Psilocybin diminished Shame-based and self-critical thought patterns.

Psilocybin significantly decreased amygdala response to angry faces (p < 0.05).

Survey of 3,000 LSD and psilocybin users: 22.5% reported adverse effects including confusion, memory issues, racing thoughts, and dissociation.

Documents the central role of the mystical/spiritual quality of experience in therapeutic outcomes.

Psilocybin increased trait mindfulness by 8.1% at 3-month follow-up — with gains strongest in those who experienced a mystical-type state.

Documents measurable neurological and psychological effects of transformative spiritual experiences, and the centrality of integration to lasting outcomes.

WHO call for innovative strategies extending beyond cognitive approaches; recognition of biologically based methods in emotional regulation.

A landmark trial published in the New England Journal of Medicine found that two doses of psilocybin performed comparably to six weeks of daily escitalopram for moderate-to-severe depression, with psilocybin showing greater improvements on several secondary outcomes.

Early use, high-frequency, and high-potency cannabis increases risk of severe cognitive and psychiatric problems, but controlled medical doses may treat neuropsychiatric conditions when the endocannabinoid system is targeted therapeutically.

In adults with PTSD, THC lowered threat-related amygdala reactivity and increased prefrontal cortex-amygdala connectivity, helping the traumatized brain regulate fear more effectively.

A microdose of LSD (13µg) altered amygdala connectivity in regions linked to emotion regulation — with changes positively correlated with mood improvement.

In patients with treatment-resistant depression, psilocybin decreased amygdala blood flow and increased brain network connectivity, with 47% meeting criteria for clinical response at five weeks — suggesting psilocybin may work by loosening rigid brain patterns associated with depression.

People with migraine, fibromyalgia, and IBS showed statistically significant lower anandamide levels, proving these conditions stem from endocannabinoid deficiency.

A landmark review established that classic psychedelics are physiologically safe, non-addictive, and act primarily through serotonin 5-HT2A receptors : laying the pharmacological foundation for their modern therapeutic resurgence.

The endocannabinoid system acts as a central integrator of fear, anxiety, and stress responses, with a particularly critical role in fear extinction — making it a direct therapeutic target for trauma and stress-related disorders.

Over 70% of the global population experiences at least one traumatic event in their lifetime, with nearly a third exposed to four or more — establishing trauma as a near-universal human experience, not an exception.

Endocannabinoids are key regulators of synaptic plasticity and neuroprotection, modulating how the brain forms, strengthens, and reorganizes neural connections — with implications for learning, memory, and recovery from neurological injury.

Cannabinoids may influence mood by interacting with endocannabinoid pathways, similarly to antidepressants — potentially impacting neurogenesis.

Psilocybin decreases activity in the brain’s default mode network , the system responsible for rumination and rigid self-narrative, with greater suppression linked to more profound subjective experiences, offering a neurobiological basis for how psychedelics may loosen entrenched thought patterns.

A landmark brain imaging study found that intense social rejection activates the same sensory brain regions as physical pain — providing neurological evidence that emotional pain is not metaphorical but measurably real, processed through the same neural machinery as a physical injury.

A meta-analysis of 146 studies confirmed that expressing difficult emotions through structured disclosure produces significant health and psychological benefits, with effects strongest when the process is guided, private, and focused on personally meaningful experiences.

The brain uses the same neural alarm system for social pain as for physical pain — centered in the anterior cingulate cortex — suggesting that rejection, exclusion, and social loss are not merely metaphorically painful, but processed through the same circuitry as bodily injury.

Foundational research establishing links between chronic Shame and Depression, Anxiety, and self-destructive behavior.

Landmark study establishing the link between unresolved emotional experience and long-term physical health outcomes.

People with 4+ adverse childhood experiences had up to 12x higher likelihood of suicide attempts and 7x higher risk of alcoholism — establishing childhood trauma as a root cause of adult disease.

Foundational study establishing emotional numbing as a clinically significant and distinct symptom cluster.